Interestingly, before receiving ENZ therapy, PCa patients with low levels of FOXA1 showed significantly higher NR3C1 transcript levels compared with PCa patients with high levels of FOXA1 (Figure 6B). The gene discussed is FOXA1; the disease is posterior cortical atrophy.